Arcutis Biotherapeutics, Inc. (ARQT) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Arcutis Biotherapeutics, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
High 26.53 at 7:30 am ET, low 25.38 at 3:45 pm ET.
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
the bull case· 3
4
of the funds on file reporting a position in ARQT
n-portas of Jun 30 '26+4.34%
change in shares held by the ten largest reporting managers over the latest quarter
13fJun 30 '26272
managers reporting a position in thirteen f filings
13fJun 30 '26the bear case· 4
6 of 23
of the largest reporting managers cut their stake in the latest quarter
13fJun 30 '2631
managers whose positions together make up four fifths of reported value
13fJun 30 '267 of 8
recent reports where the move came in under the options implied range
earnings historyimplied vs realized0.71%
of State Street SPDR S&P Biotech ETF's assets, the largest fund weight on file
n-portJun 30 '26Sides and captions by the model; every figure is ours. Built Sep 16 '26 for the Nov 3 '26 report. Not a forecast, not advice.
Of the 6 companies Arcutis Biotherapeutics, Inc. moves with most closely, none share its SEC classification.
Measured against 139 trading days of our own closes. Co-movement, not cause.
SIC 2834, Pharmaceutical Preparations, from each company's own filings. Largest first.
tall tick = annual report · 1 on record
271 managers report a position worth $3.5B between them, and 31 of them hold 80% of it.
ARQT (Arcutis Biotherapeutics, Inc.) has 3 disclosed suppliers and 3 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.